Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase

AIDS

Volumn 21, Issue 4, 2007, Pages 447-455

  Cane, Patricia A ^a   Green, Hannah ^b   Fearnhill, Esther ^b   Dunn, David ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Accessory mutations; HIV drug resistance; Reverse transcriptase inhibitors; Viral fitness

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; CODON; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

AMINO ACID SUBSTITUTION; AMINO ACIDS; ANTI-HIV AGENTS; DATABASES, FACTUAL; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33847018853     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280129964     Document Type: Article

References (14)

1. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: fall 2005. Top HIV Med 2005; 13:125-131.
2. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
3. Rhee S-Y, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, et al. HIV-1 protease and reverse-transcriptase mutations: correlations with antiviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 2005; 192:456-465.
4. Berkhout B, Back NKT, de Ronde A, Jurriaans S, Bakker M, Parkin NT, et al. Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase. AIDS 2006; 20:1515-1520.
5. UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368-1370.
6. Svicher V, Sing T, Santoro MM, Forbici F, Rodriguez-Barrios F, Bertoli A, et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006; 80:7186-7198.
7. Rothman KJ. No adjustments are needed in multiple comparisons. Epidemiology 1990; 1:43-46.
8. Sturmer M, Staszewski S, Doerr H-W, Larder B, Bloor S, Hertogs K. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211 and 214. Antimicrob Agents Chemother 2003; 47:54-61.
9. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucl Acids Res 2003; 31:298-303.
10. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39:2602-2605.
11. Winslow DL, Garber S, Reid C, Scarnati H, Baker D, Rayner MM, et al. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 1996; 10:1205-1209.
12. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000; 44:2475-2484.
13. Parkin NT, Gupta S, Chappey C, Petropoulos CJ. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2006; 50:351-354.
14. Rhee S-Y, Kantor R, Katzenstein DA, Camacho R, Morris L, Sirivichayakul S, et al. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS 2006; 20:643-651.